CoChat
Sign Up
Cited by 216Curcumin's Biomedical ApplicationsTreatment of Major DepressionTryptophan and brain disorders

The DOI matches its Crossref record; 60 of the 62 references it cites were found in a registry or an index.

Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study

Lopresti, Adrian L., Maes, Michael, Maker, Garth L., Hood, Sean D., Drummond, Peter D.·2014·Journal of Affective Disorders
DOI 10.1016/j.jad.2014.06.001
Open this paper in CoChat — free account

Abstract

Background Curcumin, the principal curcuminoid derived from the spice turmeric, influences several biological mechanisms associated with major depression, namely those associated with monoaminergic activity, immune-inflammatory and oxidative and nitrosative stress pathways, hypothalamus-pituitary-adrenal (HPA) axis activity and neuroprogression. We hypothesised that curcumin would be effective for the treatment of depressive symptoms in individuals with major depressive disorder.Methods In a randomised, double-blind, placebo-controlled study, 56 individuals with major depressive disorder were treated with curcumin (500 mg twice daily) or placebo for 8 weeks. The primary measure was the Inventory of Depressive Symptomatology self-rated version (IDS-SR30). Secondary outcomes included IDS-SR30 factor scores and the Spielberger State-Trait Anxiety Inventory (STAI).Results From baseline to week 4, both curcumin and placebo were associated with improvements in IDS-SR30 total score and most secondary outcome measures. From weeks 4 to 8, curcumin was significantly more effective than placebo in improving several mood-related symptoms, demonstrated by a significant group x time interaction for IDS-SR30 total score (F1, 53=4.22, p=.045) and IDS-SR30 mood score (F1, 53=6.51, p=.014), and a non-significant trend for STAI trait score (F1, 48=2.86, p=.097). Greater efficacy from curcumin treatment was identified in a subgroup of individuals with atypical depression.Conclusions Partial support is provided for the antidepressant effects of curcumin in people with major depressive disorder, evidenced by benefits occurring 4 to 8 weeks after treatment.Limitations Investigations with larger sample sizes, over extended treatment periods, and with varying curcumin dosages are required.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jad.2014.06.001

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 62 references

2 of the 62 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Milobedzka, 1910, Structure of curcumin, Ber. Dtsch. Chem. Ges., 43, 2163

Cited by

Sorted by citations

Items 101–200 of 216

Related

See all

Metadata

Authors
Lopresti, A. L., Maes, M., Maker, G. L., Hood, S. D., & Drummond, P. D.
Affiliations
  • Murdoch University (AU)
  • Deakin University (AU)
  • The University of Western Australia (AU)
Corresponding author
Lopresti, Adrian L.
ORCID
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2014-10
Volume
167
Pages
368-375
ISSN
0165-0327 (ISSN-L)
DOI
10.1016/j.jad.2014.06.001
OpenAlex
W2048063648
Cited by
216
References
62
Citations by year
2026: 22 · 2025: 16 · 2024: 16 · 2023: 16 · 2022: 12 · 2021: 21 · 2020: 13 · 2019: 23 · 2018: 18 · 2017: 16 · 2016: 14 · 2015: 26 · 2014: 3
FWCI
8.99
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Affective Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
  • Murdoch University Research Portal (submittedVersion)
Funders
Arjuna Natural Extracts Limited
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Curcumin's Biomedical Applications
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
curcumin, major depressive disorder, antidepressant effects, atypical depression, depressive symptoms, anxiety, neuroinflammation, oxidative stress, hypothalamic-pituitary-adrenal axis, turmeric, natural product therapy
MeSH terms
Adult, Affect, Antidepressive Agents, Curcumin, Depressive Disorder, Major, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Psychometrics, Surveys and Questionnaires, Western Australia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review